newsfilter
← Latest News
GlobeNewswire·

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of